Testing a new lung fibrosis medication against the current standard treatment

Plain-English translation of NCT07284602 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated September 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether a new medication called works better and is safer than pirfenidone, a medication already approved for treating idiopathic pulmonary fibrosis (IPF)—a condition where lung tissue becomes permanently scarred, making it harder to breathe. About 1,100 people will participate, and half will receive the new medication while the other half receives the standard treatment. The study will last at least one year, with some participants continuing for up to two years.

Idiopathic pulmonary fibrosis is a serious disease that gradually worsens over time. While pirfenidone is currently used to slow this decline, doctors are looking for treatments that may work even better. This trial will help determine if this medication can offer patients a more effective option.

Do you qualify?

You likely qualify if…

you are at least 40 years old
you have been diagnosed with idiopathic pulmonary fibrosis within the past 7 years
you have never taken pirfenidone or LYT-100 before
your lung function test shows at least 45% of normal lung capacity
you have not been hospitalized for a breathing crisis in the past 3 months

You likely don't qualify if…

you have had significant worsening of your lung disease recently or been hospitalized for breathing problems
you have emphysema (a different type of lung damage) that is more extensive than scarring
you have a condition other than IPF that could explain your lung disease
you have heart disease, significant high blood pressure in the lungs, or severe liver or kidney problems
you have smoked or used combustible cannabis within the past 3 months or cannot stop during the study

What participation looks like

You will visit the study clinic regularly over at least 52 weeks (one year). At the start, you'll have screening visits to confirm you're eligible, including breathing tests and imaging scans. Once enrolled, you'll take either the new medication or the standard treatment three times daily as capsules. You'll return for follow-up visits to have your breathing tested, blood work done, and to report how you're feeling. Depending on when you join, you may continue in the study for up to two more years to gather longer-term safety and effectiveness information.

AI-generated summary from trial data · Sep 5, 2026 · Not medical advice

Testing a new lung fibrosis medication against the current standard treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations(18 sites)